Potential interventional drugs or measures have been reported in multiple preclinical studies and the medications susceptible to be active in steatosis such as fibroblast growth factor 21 agonists, obeticholic acid or glucagon-like peptide-1 agonists deserve considerations. The gene discussed is GCG; the disease is steatosis.